Antifragile Thinking

Vikas bhai, I agree that change matters more than history. In fact, Laurus is a great example of why investors shouldn't anchor on the past. The distinction I would make is between "capability" and "validated capability". Laurus in 2019 had already built impressive scientific, manufacturing and execution capabilities. What the market questioned was whether those capabilities would ever translate into superior economics. That was the leap of faith, which is why the valuation remained modest. When I first bought it, I paid just about 1.5x P/S. That was Dec '19. What changed over the next few years wasn't just the narrative. The business established an economic reference point. Once ROCE moved to 40% in FY21 and remained well above historical levels in FY22 and FY23, investors had tangible evidence that the operating system could convert years of investment into exceptional returns on capital. Those returns were achieved after fully expensing R&D through the P&L, with no capitalisation to flatter the numbers. From that point onwards, investors were no longer underwriting possibility. They were underwriting replication. Biocon is different. R&D is not 100% expensed out. I have no doubt about the science, manufacturing capability or strategic ambition. My difficulty is that I don't yet have an equivalent economic reference point. The business has not yet demonstrated a sustained period of returns that allows me to confidently visualise what mature economics look like after fully expensing its investments in capability. Without that evidence, I find it difficult to distinguish between "latent capability" and "demonstrated capability". That's also why I don't think Syngene provides the same template as leading CRDMOs such as Anthem (peak ROCE ~50%; currently ~30%). It has built outstanding capabilities over many years, but it hasn't consistently translated those capabilities into the kind of economics that establish a reliable benchmark for future compounding. For me, investing is less about believing that a business can become exceptional than about identifying the point at which the system has shown that it has become exceptional. Laurus crossed that line between FY21 and FY23. The valuation at the next low point was double my initial entry in 2019, but post-validation, that 3x P/S was good enough for me to load it again. That 1.5x low of 2019 became 3x sales at the 2023 low cycle point. We don't know what the next low would mean in terms of P/S or in which year that next low cycle will happen, but it will probably be much higher than the previous low of 3x sales seen in 2023. The question I keep asking on Biocon is therefore not whether management can execute. It is much simpler. What is the strongest economic reference point this system has ever demonstrated, and what evidence suggests those economics are repeatable rather than aspirational? Until I can answer that with confidence, I think the odds of a Laurus-style rerating are lower. I hope your conviction beats my scepticism. We all respect @kiranshaw for her contrarian thinking and entrepreneurial courage. Those qualities built a globally respected enterprise. The remaining challenge is converting that capability into the kind of sustained economics that create enduring shareholder wealth. That's ultimately what markets reward.